person · Reporting owner

Fleming Harold Edward

Disclosed activity across 3 companies

Tapewire entity: 36884
SEC CIK: 0001857250

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
CRISPR Therapeutics AGCRSP · Entity 3852	Director	June 05, 2026	June 09, 2026
Sionna Therapeutics, Inc.SION · Entity 5996	Director	June 17, 2026	June 18, 2026
Upstream Bio, Inc.UPB · Entity 5743	Director	June 09, 2026	June 12, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

CRISPR Therapeutics AG

Report date June 05, 2026 · Filed June 09, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $51.84 · Expires 2036-06-05	Direct	13,000	Reported balance After 2026-06-05 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-05 · Grant · Acquired 13,000 · Balance 13,000 F1: Subject to continued service to the Company or any of its subsidiaries, the options will vest and become exercisable in 12 equal monthly installments on the final day of each succeeding calendar month occurring after the grant date provided that the first installment vests on June 30, 2026 and the last installment vests on the earlier of (i) the one year anniversary of the date of grant or (ii) the date of the 2027 Annual Meeting.

Filing footnotes · ownership attribution and instrument terms

F1: Subject to continued service to the Company or any of its subsidiaries, the options will vest and become exercisable in 12 equal monthly installments on the final day of each succeeding calendar month occurring after the grant date provided that the first installment vests on June 30, 2026 and the last installment vests on the earlier of (i) the one year anniversary of the date of grant or (ii) the date of the 2027 Annual Meeting.

Sionna Therapeutics, Inc.

Report date June 17, 2026 · Filed June 18, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $36.73 · Expires 2036-06-16	Direct	17,340	Reported balance After 2026-06-17 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-17 · Grant · Acquired 17,340 · Balance 17,340 F1: The Reporting Person has agreed to receive and hold for the benefit of Enavate Sciences, LP, any securities granted to him for his service as a director on the Issuer's board of directors. As such, the Reporting Person disclaims beneficial ownership of, and all right, title and interest in, the option and the shares issuable upon exercise thereof. F2: This option vests in full upon the earlier of June 17, 2027 or the date of the next annual meeting of Sionna Therapeutics, Inc., subject to the Reporting Person's continued service on such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The Reporting Person has agreed to receive and hold for the benefit of Enavate Sciences, LP, any securities granted to him for his service as a director on the Issuer's board of directors. As such, the Reporting Person disclaims beneficial ownership of, and all right, title and interest in, the option and the shares issuable upon exercise thereof.

F2: This option vests in full upon the earlier of June 17, 2027 or the date of the next annual meeting of Sionna Therapeutics, Inc., subject to the Reporting Person's continued service on such vesting date.

Upstream Bio, Inc.

Report date June 09, 2026 · Filed June 12, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.69 · Expires 2036-06-08	Direct	17,096	Reported balance After 2026-06-09 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-09 · Grant · Acquired 17,096 · Balance 17,096 F1: The shares underlying this option shall vest in full upon the earlier of (i) June 9, 2027 and (ii) the date of the next Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continued service on such vesting date. F2: Mr. Fleming has agreed to receive and hold for the benefit of Enavate Sciences, LP, any securities granted to him for his service as a director on the Issuer's board of directors. As such, Mr. Fleming disclaims beneficial ownership of, and all right, title and interest in, the option and the shares issuable upon exercise thereof.

Filing footnotes · ownership attribution and instrument terms

F1: The shares underlying this option shall vest in full upon the earlier of (i) June 9, 2027 and (ii) the date of the next Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continued service on such vesting date.

F2: Mr. Fleming has agreed to receive and hold for the benefit of Enavate Sciences, LP, any securities granted to him for his service as a director on the Issuer's board of directors. As such, Mr. Fleming disclaims beneficial ownership of, and all right, title and interest in, the option and the shares issuable upon exercise thereof.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
June 17, 2026 Filed Jun 18, 2026 21:35 UTC	Sionna Therapeutics, Inc. SION · Entity 5996	GrantNon-Qualified Stock Option (right to buy) · Derivative	17,340	$0.00 Strike: $36.73	$0.00	Disclosure SEC source: 0001857250-26-000002 · edgardoc.xml · derivative · entry 1 Fleming Harold Edward · CIK 0001857250 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,340 Underlying: Common Stock · 17,340 shares Expires 2036-06-16 F1 · security: The Reporting Person has agreed to receive and hold for the benefit of Enavate Sciences, LP, any securities granted to him for his service as a director on the Issuer's board of directors. As such, the Reporting Person disclaims beneficial ownership of, and all right, title and interest in, the option and the shares issuable upon exercise thereof. F2 · derivative.exercise_date: This option vests in full upon the earlier of June 17, 2027 or the date of the next annual meeting of Sionna Therapeutics, Inc., subject to the Reporting Person's continued service on such vesting date. Read SEC document
June 09, 2026 Filed Jun 12, 2026 00:00 UTC	Upstream Bio, Inc. UPB · Entity 5743	GrantStock Option (Right to Buy) · Derivative	17,096	$0.00 Strike: $6.69	$0.00	Disclosure SEC source: 0001193125-26-268167 · ownership.xml · derivative · entry 1 Fleming Harold Edward · CIK 0001857250 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,096 Underlying: Common Stock · 17,096 shares Expires 2036-06-08 F1 · derivative.exercise_date: The shares underlying this option shall vest in full upon the earlier of (i) June 9, 2027 and (ii) the date of the next Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continued service on such vesting date. F2 · ownership.direct: Mr. Fleming has agreed to receive and hold for the benefit of Enavate Sciences, LP, any securities granted to him for his service as a director on the Issuer's board of directors. As such, Mr. Fleming disclaims beneficial ownership of, and all right, title and interest in, the option and the shares issuable upon exercise thereof. Read SEC document
June 05, 2026 Filed Jun 9, 2026 21:43 UTC	CRISPR Therapeutics AG CRSP · Entity 3852	GrantStock Option (Right to Buy) · Derivative	13,000	$0.00 Strike: $51.84	$0.00	Disclosure SEC source: 0001193125-26-264289 · ownership.xml · derivative · entry 1 Fleming Harold Edward · CIK 0001857250 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,000 Underlying: Common Shares · 13,000 shares Expires 2036-06-05 F1 · derivative.exercise_date: Subject to continued service to the Company or any of its subsidiaries, the options will vest and become exercisable in 12 equal monthly installments on the final day of each succeeding calendar month occurring after the grant date provided that the first installment vests on June 30, 2026 and the last installment vests on the earlier of (i) the one year anniversary of the date of grant or (ii) the date of the 2027 Annual Meeting. Read SEC document
June 12, 2025 Filed Jun 16, 2025 21:07 UTC	Sionna Therapeutics, Inc. SION · Entity 5996	GrantNon-Qualified Stock Option (right to buy) · Derivative	19,959	$0.00 Strike: $16.99	$0.00	Disclosure SEC source: 0002036042-25-000029 · edgardoc.xml · derivative · entry 1 Fleming Harold Edward · CIK 0001857250 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,959 Underlying: Common Stock · 19,959 shares Expires 2035-06-11 F1 · security: The Reporting Person has agreed to receive and hold for the benefit of Enavate Sciences, LP, any securities granted to him for his service as a director on the Issuer's board of directors. As such, the Reporting Person disclaims beneficial ownership of, and all right, title and interest in, the option and the shares issuable upon exercise thereof. F2 · derivative.exercise_date: This option vests in full upon the earlier of June 12, 2026 or the date of the next annual meeting of Sionna Therapeutics, Inc., subject to the Reporting Person's continued service on such vesting date. Read SEC document
June 10, 2025 Filed Jun 12, 2025 20:17 UTC	Upstream Bio, Inc. UPB · Entity 5743	GrantStock Option (Right to Buy) · Derivative	17,096	$0.00 Strike: $11.59	$0.00	Disclosure SEC source: 0000950170-25-085372 · ownership.xml · derivative · entry 1 Fleming Harold Edward · CIK 0001857250 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,096 Underlying: Common Stock · 17,096 shares Expires 2035-06-09 F1 · derivative.exercise_date: The shares underlying this option shall vest upon the earlier of (i) June 10, 2026 and (ii) the date of the next Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continued service on such vesting date. F2 · ownership.direct: Mr. Fleming has agreed to receive and hold for the benefit of Enavate Sciences, LP, any securities granted to him for his service as a director on the Issuer's board of directors. As such, Mr. Fleming disclaims beneficial ownership of, and all right, title and interest in, the option and the shares issuable upon exercise thereof. Read SEC document
June 05, 2025 Filed Jun 6, 2025 21:30 UTC	CRISPR Therapeutics AG CRSP · Entity 3852	GrantStock Option (Right to Buy) · Derivative	13,000	$0.00 Strike: $38.57	$0.00	Disclosure SEC source: 0000950170-25-083271 · ownership.xml · derivative · entry 1 Fleming Harold Edward · CIK 0001857250 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,000 Underlying: Common Shares · 13,000 shares Expires 2035-06-05 F1 · derivative.exercise_date: This option was granted on June 5, 2025 with respect to 13,000 Common Shares, with 100% of the shares vesting in 12 equal monthly installments beginning on June 30, 2025; provided that the last installment will vest on the earlier of (i) the one year anniversary of the date of grant or (ii) the date of the 2026 Annual General Meeting of Shareholders. Read SEC document
October 10, 2024 Filed Oct 15, 2024 20:15 UTC	Upstream Bio, Inc. UPB · Entity 5743	GrantStock Option (Right to Buy) · Derivative	17,096	$0.00 Strike: $17.00	$0.00	Disclosure SEC source: 0000950170-24-114683 · ownership.xml · derivative · entry 1 Fleming Harold Edward · CIK 0001857250 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,096 Underlying: Common Stock · 17,096 shares Expires 2034-10-09 F1 · derivative.exercise_date: The shares underlying this option shall vest upon the earlier of (i) October 10, 2025 and (ii) the date of the next Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continued service on such vesting date. F2 · ownership.direct: Mr. Fleming has agreed to receive and hold for the benefit of Enavate Sciences, LP, any securities granted to him for his service as a director on the Issuer's board of directors. As such, Mr. Fleming disclaims beneficial ownership of, and all right, title and interest in, the option and the shares issuable upon exercise thereof. Read SEC document
May 30, 2024 Filed May 31, 2024 20:15 UTC	CRISPR Therapeutics AG CRSP · Entity 3852	GrantStock Option (Right to Buy) · Derivative	13,000	$0.00 Strike: $54.06	$0.00	Disclosure SEC source: 0000950170-24-067321 · ownership.xml · derivative · entry 1 Fleming Harold Edward · CIK 0001857250 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,000 Underlying: Common Shares · 13,000 shares Expires 2034-05-30 F1 · derivative.exercise_date: This option was granted on May 30, 2024 with respect to 13,000 Common Shares, with 100% of the shares vesting in 12 equal monthly installments beginning on May 31, 2024; provided that the last installment will vest on the earlier of (i) the one year anniversary of the date of grant or (ii) the date of the 2025 Annual General Meeting of Shareholders. Read SEC document
June 08, 2023 Filed Jun 9, 2023 21:34 UTC	CRISPR Therapeutics AG CRSP · Entity 3852	GrantStock Option (Right to Buy) · Derivative	13,000	$0.00 Strike: $62.59	$0.00	Disclosure SEC source: 0001209191-23-035975 · doc4.xml · derivative · entry 1 Fleming Harold Edward · CIK 0001857250 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,000 Underlying: Common Shares · 13,000 shares Expires 2033-06-08 F1 · derivative.exercise_date: This option was granted on June 8, 2023 with respect to 13,000 Common Shares with 100% of the shares vesting in 12 equal monthly installments beginning on June 30, 2023; provided that the last installment will vest on the earlier of (i) the one year anniversary of the date of grant or (ii) the date of the 2024 Annual General Meeting of Shareholders. Read SEC document
June 09, 2022 Filed Jun 10, 2022 21:36 UTC	CRISPR Therapeutics AG CRSP · Entity 3852	GrantStock Option (Right to Buy) · Derivative	12,000	$0.00 Strike: $71.70	$0.00	Disclosure SEC source: 0001209191-22-036036 · doc4.xml · derivative · entry 1 Fleming Harold Edward · CIK 0001857250 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Shares · 12,000 shares Expires 2032-06-09 F1 · derivative.exercise_date: This option was granted on June 9, 2022 with respect to 12,000 Common Shares with 100% of the shares vesting in 12 equal monthly installments beginning on June 30, 2022; provided that the last installment will vest on the earlier of (i) the one year anniversary of the date of grant or (ii) the date of the 2023 Annual General Meeting of Shareholders. Read SEC document
June 10, 2021 Filed Jun 14, 2021 21:35 UTC	CRISPR Therapeutics AG CRSP · Entity 3852	GrantStock Option (Right to Buy) · Derivative	25,000	$0.00 Strike: $123.71	$0.00	Disclosure SEC source: 0001209191-21-040291 · doc4.xml · derivative · entry 1 Fleming Harold Edward · CIK 0001857250 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Shares · 25,000 shares Expires 2031-06-10 F1 · derivative.exercise_date: This option was granted on June 10, 2021 with respect to 25,000 Common Shares with 100% of the shares vesting in 36 equal monthly installments. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.